ERBB2 and breast cancer: According to immunohistochemical markers, BC is clinically divided into the following three main subtypes to improve targeted therapy: ER (oestrogen receptor)‐positive, TNBC (triple‐negative) BC and HER‐2 (human epidermal growth factor receptor 2)‐positive.2